EVOTAZ can help you get to undetectable and increase your
T cell count
Not an actual patient
In a key 144-week clinical trial, treatment based on an EVOTAZ regimen was comparable to an atazanavir/ritonavir-based regimen.
The clinical trial
This 144-week clinical trial looked at 692 adults living with HIV, who:
- Were new to HIV therapy
- Had a moderate viral load (average of 63,096 HIV copies/mL)
- Had a weakened immune system (average CD4+ cell count of 352 cells/mm3)
- Had a normal level of kidney function (average creatinine clearance over 70 mL/min)
Patients were split into two study groups, each of which took different meds
- At 144-weeks, viral load and T cell count were measured in both trial groups.
What side effects can EVOTAZ cause?
EVOTAZ may cause side effects in some people. Some of the side effects caused by EVOTAZ can be serious.
- Talk to your prescribing physician about any side effect that may be bothering you. Your prescribing physician can work with you to handle side effects throughout your treatment.
The common moderate-to-severe side effects of EVOTAZ seen in this clinical study are:
6% of 344 patients experienced yellowing of the skin
5% of 344 patients experienced a skin rash
4% of 344 patients experienced yellowing of the white parts of the eyes
2% of 344 patients experienced nausea
2% of 344 patients experienced diarrhea
2% of 344 patients experienced headache